Sai Life Sciences to boost biology capabilities at its integrated R&D campus
.jpg)
The CRDMO will expand in vitro and in vivo biology services, DMPK and toxicology capabilities.
Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMO), plans to significantly expand its biology capabilities at its integrated R&D campus in Hyderabad, India with a dedicated 75,000 sq. ft. facility and an augmented team of 170 biologists.
The new facility will house expanded in vitro and in vivo biology services, drug metabolism and pharmacokinetics (DMPK) and toxicology capabilities with the first set of labs scheduled to open in March 2021.
According to the company's CEO & Managing Director, Krishna Kanumuri, the company aspires to deliver more than 100 development candidates for its innovator partners by 2025.
"Our growing discovery biology team co-located with our teams in medicinal chemistry, process development, process engineering and scale-up will enable us to accelerate our clients’ discovery programs through rapid turnaround times and shorter decision-making cycles,” said Kanumuri.
Sai Life Sciences has been steadily growing its biology capabilities to complement its foundation in medicinal chemistry, DMPK and toxicology for supporting its customers across the entire drug discovery journey from target identification and validation to IND.
Last year, the company opened its first international R&D facility with a biology lab in Boston, US, which offers local start-up and biotech companies biology services to address exploratory and custom biology needs.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.